Genmab A (GMAB) Short term Debt (2019 - 2026)

Genmab A's (GMAB) quarterly Short term Debt came in at $273.0 million in Q4 2025, up 1850.0% on a QoQ basis from $14.0 million in Q1 2025.

Genmab A (GMAB) Short term Debt (2019 - 2026) Analysis & Trends

Genmab A (GMAB) has 3 years of Short term Debt data on file, last reported at $273.0 million in Q4 2025.

Quarterly Short term Debt changed N/A year-over-year to $273.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $273.0 million (changed N/A YoY) and the FY2025 annual result came in at $273.0 million, changed N/A from the prior year.
Short term Debt rose to $273.0 million in Q4 2025, from $14.0 million in the prior quarter.
In the past five years, Short term Debt ranged from a high of $273.0 million in Q4 2025 to a low of $14.0 million in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Genmab A	2.05 Bn	548.77 Mn	1.07 Bn

Download Data